Diclofenac for Central Fever in Stroke: Clinical Recommendation
While diclofenac can effectively reduce body temperature in stroke patients with central fever, current guidelines provide no evidence that antipyretic treatment improves functional outcomes or survival, and diclofenac carries significant cardiovascular and hepatic risks that are particularly concerning in the acute stroke population.
Evidence-Based Framework
Guideline Position on Antipyretics in Stroke
The 2015 European Stroke Organisation (ESO) guidelines explicitly state they cannot make any recommendation for treating hyperthermia as a means to improve functional outcome and/or survival in acute ischemic stroke patients 1. This neutral stance reflects:
- Very low to low quality evidence
- No demonstrated benefit on mortality or functional outcomes
- Weak strength of recommendation
The guidelines acknowledge that antipyretics may be given to relieve discomfort associated with hyperthermia, but this is distinct from improving clinical outcomes 1.
Critical Care Perspective
The 2023 Society of Critical Care Medicine guidelines suggest avoiding routine use of antipyretic medications for the specific purpose of reducing temperature in critically ill patients with fever (weak recommendation, moderate quality evidence) 2. However, they do suggest using antipyretics over nonpharmacologic methods if patients value comfort by reducing temperature 2.
Diclofenac-Specific Considerations
Efficacy Data
Research demonstrates diclofenac can effectively reduce body temperature in neurologically injured patients:
- Low-dose continuous infusion (0.04 mg/kg/h) achieved normothermia (<37.5°C) in acute cerebral damage patients 3
- Single IV bolus (0.2 mg/kg) reduced temperature by >0.5°C within 1 hour in 90% of ICU patients 4
- A systematic review confirmed diclofenac reduces body temperature (mean difference 1.10°C) in neurocritical care 5
Critical Safety Concerns
Cardiovascular Risks:
- Diclofenac increases major adverse cardiovascular events by approximately 50% (IRR 1.53) 6
- Risk elevation occurs with both high (≥150 mg/day) and low (<150 mg/day) doses 6
- This is particularly problematic in stroke patients who already have elevated cardiovascular risk
- The FDA label warns of increased risk of myocardial infarction and stroke with NSAIDs 7
Hepatotoxicity:
- Approximately 4% of patients develop meaningful ALT/AST elevations 7
- Severe hepatic reactions including liver necrosis and fulminant hepatitis have been reported 7
- Most elevations occur within the first 2 months but can happen anytime 7
- Requires baseline and periodic transaminase monitoring within 4-8 weeks 7
Renal Toxicity:
- NSAIDs can cause dose-dependent reduction in renal perfusion 7
- Highest risk in patients with heart failure, dehydration, or on ACE inhibitors/diuretics 7
- Common comorbidities in stroke patients
Clinical Algorithm for Decision-Making
Step 1: Establish Fever Etiology
- Rule out infection first - obtain chest X-ray, cultures, inflammatory markers 2
- Central fever diagnosis requires: early onset (typically day 1-3), hypothalamic/brainstem involvement, absence of infection, and negative cultures 8
- Consider alternative diagnoses (drug fever, DVT, etc.)
Step 2: Assess Need for Treatment
Treat if:
- Patient experiencing significant discomfort from fever
- Temperature >38.3°C causing distress
Do NOT treat if:
- Goal is to improve stroke outcomes (no evidence of benefit)
- Patient is asymptomatic from fever
Step 3: Risk Stratification for Diclofenac
Absolute contraindications:
- Recent MI or active cardiovascular disease
- Severe heart failure
- Hepatic dysfunction or elevated transaminases
- Renal impairment
- History of GI bleeding
Relative contraindications:
- Hypertension
- On antiplatelet agents beyond aspirin
- Dehydration or hypovolemia
Step 4: Treatment Selection
First-line approach:
- Acetaminophen (paracetamol) remains safer despite limited efficacy 9
- Maximum 3 grams/day to avoid hepatotoxicity 9
- Physical cooling methods if acetaminophen inadequate
If considering diclofenac:
Dosing regimen based on research:
- IV bolus: 0.2 mg/kg in 100 mL saline over 30 minutes 10
- Continuous infusion: 0.04 mg/kg/h (approximately 75 mg in 50 mL saline over 24 hours for 70 kg patient) 3
- Alternative: 75 mg IV brief infusion 4, 11
Monitoring requirements:
- Baseline liver function tests, renal function, CBC
- Blood pressure monitoring
- Repeat LFTs within 4-8 weeks if prolonged use 7
- Assess volume status before initiation 7
- Monitor for signs of hepatotoxicity (nausea, jaundice, RUQ pain) 7
Duration:
- Limit to shortest duration possible (typically 2-5 days) 10, 3
- Discontinue once normothermia achieved
Common Pitfalls to Avoid
Treating fever to improve stroke outcomes - No evidence supports this; only treat for symptom relief 1
Using standard oral dosing - Research supporting diclofenac in central fever used low-dose IV continuous infusion, not standard oral doses 3
Ignoring cardiovascular risk - The cardiovascular risk is dose-independent and particularly dangerous in stroke patients 6
Failing to monitor liver function - Hepatotoxicity can occur rapidly and without warning 7
Assuming central fever diagnosis prematurely - Always exclude infection thoroughly first 8
Combining with other hepatotoxic drugs - Avoid concurrent acetaminophen or other potentially hepatotoxic agents 7
Alternative Consideration
Recent case reports suggest gabapentin may have a role in central fever management 12, though this requires further investigation. Physical cooling methods remain an option when pharmacologic approaches are contraindicated.
Bottom Line
Given the lack of outcome benefit, significant cardiovascular risks (particularly in stroke patients), and hepatotoxicity concerns, diclofenac should be reserved only for refractory central fever causing significant patient discomfort when acetaminophen and physical cooling have failed, and only after careful cardiovascular and hepatic risk assessment. When used, employ low-dose IV continuous infusion (0.04 mg/kg/h) with close monitoring for the shortest duration possible 3, 5.